Related Experiment Video
Updated: May 13, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
HCV versus HIV drug discovery: Déjà vu all over again?
William J Watkins1, Manoj C Desai
1Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA. will.watkins@gilead.com
Abstract:
Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral replication with once-daily regimens. More recent research into HCV therapeutics have also resulted in very promising clinical candidates. This Digest explores similarities and differences in the two fields and compares the chronology of drug discovery relative to the availability of enabling tools, and concludes that safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than was the case for HIV.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Drug Discovery: Overview
Viruses with RNA Genomes
Pharmacogenomics: Identification of New Drug Targets
Hepatitis
Inhibitors of Viral Protein Synthesis

